AstraZeneca and China International Capital to launch $1 bln China biotech venture fund: Bloomberg
U.S. drugmaker AstraZeneca and China International Capital Corp are teaming up to launch a $1 billion China-focused biotech venture fund, reported Bloomberg. The news outlet added that AstraZeneca will not be a majority investor, according to CEO Pascal Soriot.
6 November 2019•1 min read
